AC Immune has announced positive early findings from its Phase 1 study of a new NLRP3 inhibitor, known as ACI-19764. While further details remain behind a paywall, the initial results signal hopeful progress for this experimental approach.

A recent publication warns of potential dangers associated with compounded oral GLP-1 medications, although detailed information remains behind paid access. The article underscores a growing need for healthcare professionals and patients to stay alert to emerging risks.

A new article highlights Orforglipron, Cagrilintide, and the Libre Assist as potential breakthroughs in diabetes management, though the complete details remain behind a paywall. Published by Hcplive, the piece underscores the continued push toward innovative therapies and technologies for people living with diabetes.